Biotech

All Articles

Sanofi flunks MS research, inflicting one more impact to Denali contract

.Sanofi has quit a stage 2 hardship of Denali Therapeutics-partnered oditrasertib in a number of scl...

Turnstone gives up 60%, shakes up C-suite to stretch out cash money

.Turnstone Biologics is actually lowering its own headcount by 60% and shaking up its C-suite so as ...

Gilead loses hope on $15M MASH wager after weighing preclinical information

.In a year that has actually observed an authorization and a range of readouts for metabolic dysfunc...

Texas biotech centers cancer cells treaty, pins hopes on excessive weight

.Alaunos Rehabs is axing a contract with Precigen, quiting licensing rights to a personalized T-cell...

Capricor allotments much more records for DMD therapy after starting BLA

.Capricor Therapies is actually taking a triumph tour for their phase 2 Duchenne muscle dystrophy (D...

FDA locations Kezar lupus trial in hold observing 4 client deaths

.The FDA has put Kezar Lifestyle Sciences' lupus trial on hold after the biotech flagged 4 fatalitie...

Phase 3 Historian Stone trial reaches SMA target, delivering stockpile 200%

.A stage 3 test of Academic Stone's spinal muscle atrophy (SMA) prospect has actually reached its ow...

CAMP 4 is most current to eye IPO, while Upstream define $182M plan

.RNA biotech CAMP4 Rehabs has defined plans for a $67 million IPO, along with inflammation-focused U...

Galecto acquires leukemia drug, goes down bone tissue cancer cells asset in pivot

.A year after the failing of an idiopathic lung fibrosis candidate sent out Galecto on a hunt for sa...

Judo tosses down $100M to knock senseless kidney illness

.Taking the floor covering is Judo Bio, a promising biotech armed with $one hundred thousand to crea...